Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02977780
Title INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

gliosarcoma

glioblastoma

Therapies

CC-115

Abemaciclib + Temozolomide

Temozolomide

Neratinib + Temozolomide

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Alabama at Birmingham Birmingham Alabama 35294 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02115 United States Details
Mayo Clinic Rochester Minnesota 55905 United States Details
Columbia University Medical Center New York New York 10032 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Cleveland Clinic Cleveland Ohio 44195 United States Details
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15232 United States Details
Lifespan / Rhode Island Hospital Providence Rhode Island 02903 United States Details
UT MD Anderson Cancer Center Houston Texas 77030 United States Details
Huntsman Cancer Institute Salt Lake City Utah 84112 United States Details
University of Virginia Health System Charlottesville Virginia 22908 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field